MoonLake Immunotherapeutics — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. MoonLake is a clinical-stage biotechnology company developing sonelokimab (SLK), an IL-17A/IL-17F inhibitor, initially for hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). It has no approved products and has generated no product revenue.
Financial results and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $8.7 million | $11.4 million | $16.1 million | $21.7 million |
| General and administrative expense | $4.5 million | $6.3 million | $10.0 million | $11.9 million |
| Net loss | $12.4 million | $17.4 million | $24.6 million | $33.3 million |
| Net loss per Class A share | $0.23 | $0.34 | $0.46 | $1.13 |
| Operating cash used | Not separately stated | Not separately stated | $21.2 million | $34.9 million |
Margins are not meaningful because the company has no product revenue. Other income was $0.8 million for Q2 and $1.6 million for the first half, primarily reflecting interest income and foreign-exchange gains.
At June 30, cash and cash equivalents were $501.8 million, compared with $39.5 million at December 31, 2022; there were no marketable debt securities outstanding. Current assets were $506.4 million and current liabilities $7.1 million. Total liabilities were $7.5 million, including operating lease liabilities; the filing reports no borrowings outstanding. Management believes current cash can fund operations and capital expenditure requirements until 2026.
Six-month investing cash inflow of $32.3 million mainly came from maturities of short-term securities. Financing cash inflow was $451.3 million, primarily from equity sales. Cash increased $462.3 million during the period.
Changes versus prior comparable period
- Q2 net loss narrowed by 29% year over year; first-half net loss narrowed by 26%.
- First-half R&D expense declined 26%, principally because of lower SLK license-related research and milestone expenses and lower clinical-trial supply and logistics costs. These reductions partly offset increased CRO trial costs and other development spending.
- First-half G&A expense declined 16%, primarily reflecting lower public-company and transaction-related professional fees and share-based compensation.
- Cash rose substantially following equity financing. The June public offering generated $436.7 million net; ATM sales generated approximately $14.6 million net. The company issued 9.7 million Class A shares during the first half, increasing potential shareholder dilution.
Outlook, risks and unusual items
- In June, MoonLake reported positive topline MIRA Phase 2 results in HS, meeting the primary HiSCR75 endpoint. It expected 24-week topline data in mid-October 2023. The ARGO Phase 2 PsA trial completed patient randomization in July, with a primary-endpoint readout expected in the first half of November 2023.
- Management expects significant operating losses for at least the next four years and anticipates higher costs as development advances, including potential Phase 3 trials and commercialization preparation. Clinical outcomes, regulatory timing, trial enrollment and costs remain uncertain; additional capital may eventually be needed.
- SLK is licensed from Merck Healthcare KGaA. Additional contingent license milestones of up to €299.6 million (approximately $325.1 million at the June 30 exchange rate) may become payable on specified regulatory and commercial events. Related agreements provide for royalties in the low-to-mid-teen percentage range of net sales.
- Unrecognized contractual purchase commitments were $20.1 million, principally for clinical research and manufacturing; $14.6 million was due within one year. These are separate from potential future milestone payments.
- The company said there were no material changes to previously reported risk factors and no material legal proceedings. Management judged disclosure controls effective as of June 30. It expected to lose emerging-growth-company and smaller-reporting-company status at year-end 2023, potentially increasing reporting and audit requirements.
Important facts for investors to verify
- Review the full MIRA efficacy and safety results and the announced ARGO readout timing; both are important clinical catalysts, not established commercial outcomes.
- Track actual cash burn, trial spending and management’s cash-runway estimate as clinical programs progress.
- Assess future share issuance and dilution, including any renewed ATM sales; the ATM’s stated sale limit was reduced to zero unless a further prospectus supplement is filed.
- Review the terms and triggers for the potential license milestones, royalties and outstanding clinical/manufacturing commitments.
- Confirm the timing and consequences of the expected filer-status changes and any resulting internal-control attestation requirements.